191 related articles for article (PubMed ID: 27243342)
1. Extrinsic blood coagulation pathway and risk factors for thrombotic events in patients with essential thrombocythemia.
Stankowska K; Gadomska G; Boinska J; Michalska M; Bartoszewska-Kubiak A; Rość D
Pol Arch Med Wewn; 2016 May; 126(5):340-6. PubMed ID: 27243342
[TBL] [Abstract][Full Text] [Related]
2. Activation of the tissue factor-dependent extrinsic pathway and its relation to JAK2 V617F mutation status in patients with essential thrombocythemia.
Gadomska G; Stankowska K; Boinska J; Bartoszewska-Kubiak A; Haus O; Rość D
Blood Coagul Fibrinolysis; 2016 Oct; 27(7):817-821. PubMed ID: 26945263
[TBL] [Abstract][Full Text] [Related]
3. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
[TBL] [Abstract][Full Text] [Related]
4. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Colomer D; Villamor N; Bellosillo B; Cervantes F
Am J Hematol; 2009 Feb; 84(2):102-8. PubMed ID: 19105233
[TBL] [Abstract][Full Text] [Related]
5. Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients.
Chim CS; Sim JP; Chan CC; Kho BC; Chan JC; Wong LG; Law M; Liang R; Kwong YL
Hematology; 2010 Aug; 15(4):187-92. PubMed ID: 20670476
[TBL] [Abstract][Full Text] [Related]
6. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
Weston H; Cowell V; Grimmett K; Saal R; Jones M; Mills T; Gill D; Marlton P; Bird R; Mollee P
Intern Med J; 2011 May; 41(5):408-15. PubMed ID: 20681956
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors of thrombosis for patients with essential thrombocythaemia: A single center study.
Prajs I; Kuliczkowski K
Adv Clin Exp Med; 2017; 26(1):115-121. PubMed ID: 28397442
[TBL] [Abstract][Full Text] [Related]
9. Activation of TF-Dependent Blood Coagulation Pathway and VEGF-A in Patients with Essential Thrombocythemia.
Gadomska G; Ziołkowska K; Boinska J; Filipiak J; Rość D
Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30781507
[No Abstract] [Full Text] [Related]
10. JAK-2 V617F mutation increases heparanase procoagulant activity.
Kogan I; Chap D; Hoffman R; Axelman E; Brenner B; Nadir Y
Thromb Haemost; 2016 Jan; 115(1):73-80. PubMed ID: 26489695
[TBL] [Abstract][Full Text] [Related]
11. Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.
Santoro M; Accurso V; Mancuso S; Carlisi M; Raso S; Tarantino G; Di Piazza F; Perez A; Russo A; Siragusa S
Hematol Oncol; 2019 Oct; 37(4):434-437. PubMed ID: 31465530
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Hematology; 2008 Apr; 13(2):71-6. PubMed ID: 18616871
[TBL] [Abstract][Full Text] [Related]
13. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia.
De Stefano V; Za T; Rossi E; Fiorini A; Ciminello A; Luzzi C; Chiusolo P; Sica S; Leone G
Haematologica; 2009 May; 94(5):733-7. PubMed ID: 19336736
[TBL] [Abstract][Full Text] [Related]
14. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.
Hsiao HH; Yang MY; Liu YC; Lee CP; Yang WC; Liu TC; Chang CS; Lin SF
Exp Hematol; 2007 Nov; 35(11):1704-7. PubMed ID: 17920754
[TBL] [Abstract][Full Text] [Related]
15. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia.
Trifa AP; Cucuianu A; Popp RA; Coadă CA; Costache RM; Militaru MS; Vesa ŞC; Pop IV
Ann Hematol; 2014 Feb; 93(2):203-9. PubMed ID: 23828072
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
[TBL] [Abstract][Full Text] [Related]
17. Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea.
Lee HS; Park LC; Lee EM; Lee SJ; Shin SH; Im H; Do KM; Kim EJ; Ye BJ; Song MK; Kim SH; Lee SM; Lee WS; Kim YS
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):70-5. PubMed ID: 22088920
[TBL] [Abstract][Full Text] [Related]
18. JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients.
Sokołowska B; Nowaczyńska A; Bykowska K; Chocholska S; Wejksza K; Walter-Croneck A; Gromek T; Kowalska AM; Kandefer-Szerszeń M; Dmoszyńska A
Folia Histochem Cytobiol; 2011; 49(2):267-71. PubMed ID: 21744327
[TBL] [Abstract][Full Text] [Related]
19. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.
Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Villamor N; Colomer D; Cervantes F
Haematologica; 2006 Feb; 91(2):169-75. PubMed ID: 16461300
[TBL] [Abstract][Full Text] [Related]
20. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
